Olufunmilayo Olopade to Cohort Studies
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Cohort Studies.
Connection Strength
0.834
-
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
Score: 0.131
-
Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
Score: 0.063
-
High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012 Sep 01; 131(5):1114-23.
Score: 0.061
-
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012 Jan 15; 18(2):350-9.
Score: 0.060
-
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
Score: 0.051
-
Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
Score: 0.048
-
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
Score: 0.039
-
Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
Score: 0.033
-
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018 09 15; 78(18):5419-5430.
Score: 0.024
-
Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
Score: 0.022
-
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
Score: 0.022
-
Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
Score: 0.020
-
The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):231-8.
Score: 0.020
-
Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast. 2015 Apr; 24(2):131-6.
Score: 0.019
-
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
Score: 0.018
-
The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2013 Nov; 142(1):177-85.
Score: 0.017
-
A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48.
Score: 0.016
-
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1362-70.
Score: 0.016
-
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
Score: 0.015
-
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805.
Score: 0.015
-
Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
Score: 0.015
-
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
Score: 0.014
-
Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2011 May; 20(5):1032-8.
Score: 0.014
-
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 2009; 11(5):R76.
Score: 0.012
-
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008 Jun; 40(6):703-6.
Score: 0.012
-
Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008 Feb 15; 148C(1):70-7.
Score: 0.012
-
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
Score: 0.010
-
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006; 8(2):R23.
Score: 0.010
-
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10.
Score: 0.010
-
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005 Jan; 96(1):222-6.
Score: 0.009
-
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
Score: 0.007